ISSN:
1432-1041
Schlagwort(e):
liver cirrhosis
;
nadolol
;
portal hypertension
;
liver circulation/-function
;
aminopyrine
;
galactose elimination
;
indocyanine green clearance
Quelle:
Springer Online Journal Archives 1860-2000
Thema:
Chemie und Pharmazie
,
Medizin
Notizen:
Summary Nadolol, a non-cardioselective beta adrenoreceptor blocking agent, has been reported to decrease portal pressure without affecting liver function in cirrhotic patients treated for 1 month. There were no data about the long-term effects of nadolol on liver function. In 11 patients with cirrhosis and portal hypertension galactose eliminating capacity, aminopyrine metabolic capacity, ICG clearance and IGC intrinsic hepatic clearance according to the “parallel tube” model were measured before and after 6 months of treatment with nadolol at a dose reducing resting heart rate by approximately 25%. No significant variation in any of these parameters was found. Thus 6 months of continuous oral administration of nadolol did not further impair liver function in cirrhotics.
Materialart:
Digitale Medien
URL:
http://dx.doi.org/10.1007/BF01046709
Permalink
